Related Experiment Video
Updated: May 11, 2026
12:49
Human Peripheral Blood Neutrophil Isolation for Interrogating the Parkinson's Associated LRRK2 Kinase Pathway by Assessing Rab10 Phosphorylation
Published on: March 21, 2020
The development of CNS-active LRRK2 inhibitors using property-directed optimisation
Madeline E Kavanagh1, Munikumar Reddy Doddareddy, Michael Kassiou
1School of Chemistry, The University of Sydney, Sydney, NSW 2006, Australia.
Bioorganic & Medicinal Chemistry Letters
|June 1, 2013
Summary
Researchers developed GNE-7915, a potent and selective inhibitor targeting Leucine-Rich Repeat Kinase 2 (LRRK2) mutations. This breakthrough offers a novel therapeutic strategy for Parkinson's disease by addressing its genetic roots.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Mutations in the PARK8 gene, encoding Leucine-Rich Repeat Kinase 2 (LRRK2), are a leading genetic cause of Parkinson's disease.
- Inhibiting LRRK2 kinase activity demonstrates neuroprotective effects, offering a potential way to target the disease's biochemical basis.
- Previous efforts to develop LRRK2 inhibitors faced challenges with traditional drug discovery screening methods.
Purpose of the Study:
- To report the development of a novel, potent, selective, brain-penetrant, and non-toxic inhibitor of LRRK2.
- To showcase an optimized approach to early-stage drug development focusing on multiple key properties.
Main Methods:
- Utilized in silico modeling for rational drug design.
- Conducted extensive in vitro assays to evaluate potency and selectivity.
- Employed resource-efficient in vivo techniques for pharmacokinetic and safety assessments.
Main Results:
- Identified and characterized GNE-7915, an amino-pyrimidine derivative.
- GNE-7915 demonstrated high potency with an IC50 of 9 nM against LRRK2.
- The inhibitor exhibited significant selectivity, inhibiting only 1 out of 187 kinases tested, and possessed favorable brain penetration and safety profiles.
Conclusions:
- GNE-7915 represents a promising therapeutic candidate for Parkinson's disease, directly targeting the underlying LRRK2 genetic defect.
- The development strategy for GNE-7915 highlights a successful shift towards integrated optimization of potency, selectivity, and pharmacokinetics in early drug discovery.
